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Summary 
The cytoplasmic C-terminus of Epstein-Ban' virus (EBV) 
latent infection membrane protein 1 (LMP1) is essen- 
tial for B lymphocyte growth transformation and is now 
shown to interact with a novel human protein (LMP1- 
associated protein 1 [LAP1]). LAP1 is homologous to 
a murine protein, tumor necrosis factor receptor- 
associated factor 2 (TRAF2), implicated in growth sig- 
naling from the p80 TNFR. A second novel protein (EBI6), 
induced by EBV infection, is the human homolog of 
a second murine TNFR-associated protein (TRAF1). 
LMP1 expression causes LAP1 and EBI6 to localize to 
LMP1 clusters in lymphoblast plasma membranes, 
and LMP1 coimmunoprecipitates with these proteins. 
LAP1 binds to the p80 TNFR, CD40, and the lympho- 
toxin-p receptor, while EBI6 associates with the p80 
TNFR. The interaction of LMP1 with these TNFR fam- 
ily-associated proteins is further evidence for their 
role in signaling and links LMPl-mediated transforma- 
tion to signal transduction from the TNFR family. 
Introduction 
Epstein-Barr virus (EBV) causes infectious mononucleosis 
and lymphoproliferative diseases in immune-suppressed 
patients. EBV is also an important etiologic factor in en- 
demic Burkitt's lymphoma, AIDS-associated central ner- 
vous system lymphomas, Hodgkin's disease, and naso- 
pharyngeal carcinoma (Kieff and Liebowitz, 1990; Miller, 
1990). EBV infection of B lymphocytes is primarily nonlytic, 
resulting in the expression of EBV-encoded nuclear 
(EBNAs) and integral membrane proteins (latent infection 
membrane proteins [LMPs]) as well as perpetual cell prolif- 
eration (Kieff and Liebowitz, 1990). EBV recombinant- 
based molecular genetic analyses have demonstrated that 
LMP1 and EBNA2, -LP, -3A, and -3C are critical for B 
lymphocyte transformation (Cohen et al., 1989; Ham- 
merschmidt and Sugden, 1989; Kieff and Liebowitz, 1990; 
Mannick et al., 1991; Kaye et al., 1993; Tomkinson et al., 
1993), while LMP2, EBNA3B, the EBV-encoded small 
RNAs and most of the rest of the genome are dispensable 
(Marchini et al., 1991; Swaminathan et al., 1991; Long- 
necker et al., 1993; Tomkinson and Kieff, 1992; Robertson 
et al., 1994). EBNA1 is also important for transformation 
since it enhances transcription and replication from EBV 
episomes (Yates et al., 1984; Reisman and Sugden, 1986). 
LMP1 is not only essential for primary B lymphocyte 
growth transformation but is also the only EBV gene that 
has transforming effects in nonlymphoid cells. In Rat1 
cells, LMP1 induces growth in lower serum, loss of contact 
inhibition, anchorage independence, and nude mouse tu- 
morigenicity, while in BALB/c 3T3 cells, LMP1 induces 
anchorage-independent growth (Wang et al., 1985, 1988a; 
Baichwal and Sugden, 1988; Moorthy and Thorley- 
Lawson, 1993). In B lymphoblasts, LMP1 induces most of 
the phenotypic effects of EBV infection, including induced 
expression of activation markers and adhesion molecules, 
altered growth, and NF-~:B activation (Wang et al., 1988b, 
1990; Hammarskjold and Simurda, 1992; Laherty et al., 
1992; Rowe et al., 1994). In epithelial cells, LMP1 blocks 
differentiation (Dawson et al., 1990; Fahraeus et al., 1990; 
Wilson et al., 1990). These activities are probably relevant 
to tumorigenicity inhumans since LMP1 is expressed not 
only in EBV-induced lymphoproliferative disease but also 
in EBV-associated Hodgkin's disease tumor cells and in 
most anaplastic nasopharyngeal carcinoma cells (Herbst 
et al., 1991; Pailesen et al., 1991; Brooks et al., 1992; 
Busson et al., 1992). 
LMP1 is an integral membrane protein that may trans- 
form cells by constitutively activating a growth factor re- 
ceptor pathway common to many cell types (Wang et al., 
1985). LMP1 consists of a 23 amino acid amino-terminal 
cytoplasmic domain, 6 markedly hydrophobic transmem- 
brane domains separated by short reverse turns, and a 
200 amino acid carboxy-terminal cytoplasmic domain 
(Fennewald et al., 1984; Hennessy et al., 1984). The trans- 
membrane domains enable LMP1 to posttranslationally 
insert into membranes and to accumulate in aggregates 
in the plasma membrane (Hennessy et al., 1984; Liebowitz 
et al., 1986). 
Recent genetic analyses in primary B lymphocyte growth 
transformation indicate that the amino terminus is im- 
portant for tethering of the first transmembrane domain, 
and the transmembrane domains are important for confer- 
ring plasma membrane aggregation (Kaye et al., 1993, 
1995; Izumi et al., 1994). EBV recombinants deleted for 
the entire 200 or for the last 155 amino acids of the LMP1 
carboxy-terminal cytoplasmic domain are incapable of 
transforming primary B lymphocytes (Kaye et al., 1995). 
While the nontransforming phenotype of EBV recombi- 
nants deleted for the last 155 amino acids of LMP1 can 
be transcomplemented by the growth of infected lympho- 
cytes on fibroblast feeders, to date it has not been possible 
to similarly rescue primary B lymphocytes infected with 
EBV recombinants deleted for the entire 200 amino acid 
carboxy-terminal cytoplasmic domain (Kaye et al., 1995). 
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Figure I. AminoAcidAl ignmentofHuman [::Bi6and LAPI andMurine 
TRAF1 and TRAF2 
The four polypeptide sequences were aligned using the CLUSTAL 
.program (PCGene [IntelliGenetics]). Identical (asterisks) and homolo- 
gous (dots) amino acids are shown. Pairwise alignment of EBI6 and 
TRAF1 is also Shown, witi~ identical amino acids designated by bold 
faced characters. Amino acidsthat form the RING finger motif in LAP1 
and TRAF2 and the zinc finger s~trdcture in EBI6 and TRAF1 are under- 
lined. Amino acids that form putative coiled-coil structures are boxed. 
[he TRAF domain is shown by large boxes. 
These results implicate the LM P1 carboxyl terminus in cell 
growth transformation and suggest that the first 44 amino 
acids ,may ,be stringently required for transformed cell 
growth (Kaye et al., 1995). We have now discovered that 
the first 44 amino acids of the LMP1 carboxy-terminal cyto- 
plasmic domain interact with a human protein related to 
the very recently described putative ffectors of tumor ne- 
crosis factor receptor (TNFR) signaling (Rothe et al., 
1994). The interaction of this human protein with LMP1 
and with the cytoplasmic domains of the TNFR family 
members is evidence for a central role of this protein as 
an effector of cell growth or death signaling pathways. 
Results 
A Yeast Two.Hybrid Screen Reveals Proteins That 
Interact with the LMP1 Carboxy-Terminal 
Cytoplasmic Domain 
DNA encoding the200 amino acid LMP1 carboxy-terminal 
Table 1. 13-Gal Assay of Protein-Protein Interactions inthe Yeast 
Two-Hybrid System 
Transformant 13-Gal Units 
G4DBDLMP1(187-386)-G4TADLAP 1(183-568) 56 
G4DBDLMP1(187-386)-G4TAD LAP 1(346-568) 8 
G4DBDLM P 1(187-231)-G4TAD LAP1(183-568) 5 
G4DBD LM P 1(167-231)-G4TAD LAP 1 (346-568) 5 
G4DBDLM Pl(187-386)-G4TADEBI6(53-416) 0.07 
G4DBDLAP 1(12-568)-G4TADEBI6(53-416) 0.07 
G4DBDLM P1(187-386) 0.04 
G4DBDLM P1 (187-231 ) 0.09 
G4DBDLAP1 (183-568) 0.04 
G4TADLAPI(187-568) 0. t 
G4TADEBI6(53-416) 0.04 
G4DBDLAPI(t 2-568) 0.05 
G4DBDSNF1-G4TADSNF4 0.8 
The yeast strain Y190 was transformed with the indicated plasmids, 
and transformants were selected on appropriate s lective-defined me- 
dia. Isolated colonies were grown to mid to late log density and assayed 
for I~-gal activity as described in Experimental Procedures. Four indi- 
vidual transformants were assayed in each case (except for the interac- 
tion between G4DBDSNF1 and G4TADSNF4, for which two trans- 
formants were tested), and the average values of ~,-Gal units are 
shown. The interaction between G4DBDSNF1 and G4TADSNF4 was 
used as a positive control (Harper et al., 1993) and scored 0.8 ~-gal 
units or higher in different assays. 
cytoplasmic domain was fused in frame to the GAL4 DNA- 
binding domain for use as bait in a yeast two-hybrid screen 
for cDNAs that encode interactive proteins. The GAL4- 
activating domain was fused to cDNAs made from RNA 
from EBV-transformed B lymphocytes (Durfee et al., 
1993). Of 5 x 10 s transformants that were tested for 
growth in the absence of tryptophane, leucine, and histi- 
dine and in the presence of 25 mM 3-aminotriazole, 147 
colonies showed at least moderate growth and were ana- 
lyzed for ~-galactosidase (15-gal) expression. Two clones 
were strongly positive for 13-gal, scoring higher than 8 U 
in a standard 13-gal assay, whereas the rest of the clones 
had nearly background levels of 13-gal activity (less than 
0.04 U). The GAL4-activating domain-fusion proteins 
made from these two clones did not interact with GAL4 
DNA-binding domain fusions to p53, pRB, lamin, or the 
yeast protein kinase SNF1, indicating specificity for the 
LMP1 cytoplasmic carboxyl terminus. The two clones 
were 3' coterminal cDNAs from the same mRNA. The 
clones have a single long open reading frame predicted 
to encode part of a novel protein provisionally designated 
LMPl-associated protein 1 (LAP1). To obtain the full- 
length LAP1 open reading frame, the insert from the longer 
clone was used to identify clones from a Xgtl0 library of 
cDNAs (Birkenbach et ai., 1993) prepared from RNA from 
an EBV-infected B lymphoblast cell line, BL41/B95-8. One 
clone has the beginning and most of the 568 codon LAP1 
open reading frame, whereas two other clones were de- 
rived from an alternatively spliced mRNA that lacks 1061 
bases, including the first 320 codons of LAP1. 
From thesequence of the complete open reading frame, 
full-length LAP1 is predicted to have an amino-terminal 
RING finge.r metal-binding motif and a carboxy-terminal 
domain that begins with an extended coiled-coil motif (Fig- 
EBV LMP1 Transformation and TNFR Family Signaling 
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Figure 2. LAP1 and EBI6 mRNA Abundance 
Northern blot of RNA from human tissues (A 
and B, both poly(A) + RNA) or cell lines ((3 and 
D, poly(A) + RNA~ and total RNA, respecti~ely,~', 
hybridized with LAP1 (A and C) or EBI6~(B;andJ 
D) probes. The probe is shown belQw the,blot~, 
and the origin of RNA is shown above each. 
lane. Size markers are to the left of each blot, 
and arrows indicate ~e position of specifically 
and consistently detected mRNAs. The LAP1 
probe detected 2.8 kb and 1.8 kb RNAs, 
whereas the EBI6 probe~detected e 2.6 kb RNA. 
The high molecular weight bands were not con- 
sistently detected in other Northern blots with 
these probes. LAP1 (C) a~d EBI6 (D) mRNAs 
were also detected in RNA from EBV-infected 
BL41 (BL41/B95-8), EBV-neg~tive SL41 (BL41), 
and EBV-transformed (IS4) cells. An actin 
probe (ACTIN) indicates the relative amounts 
of RNA in (C) and (D). 
Abbreviations: PA, pancreas, KI, kidney, SM, 
skeletal muscle, LI, liver, LU, lu~ng, PL, pla- 
centa, BR, brain, and HE, heart. 
ACTIN ACTIN 
ure 1). The carboxy-terminal LAP1 domain (amino acids 
302-568) has 45% colinear amino acid identity to the 
TNFR-associated factor (TRAF) homology domain of the 
recently identified murine TRAF1 or -2 (Rothe et al., 1994). 
LAP1 is similar to TRAF2 in having an amino-terminal 
RING finger motif, but is only 27% identical to TRAF2 
overall. The longest open reading frame identified in the 
alternatively spliced LAP1 mRNA encodes for a polypep- 
tide that initiates at methionine codon 350 within the 
coiled-coil motif of full-length LAP1 and includes the rest 
of the TRAF domain. Since amino acids 345-568 of LAP1 
interact strongly with the LMP1 carboxy-terminal cyto- 
plasmic domain (Table 1), the protein encoded by the 
spliced LAP1 m RNA is likely to interact also with the LM P1 
carboxy-terminal cytoplasmic domain and could modulate 
interactions of LAP1 with LMP1. 
A Carboxy-Terminal LAP1 Domain Interacts with a 
LMP1 Membrane Proximal Cytoplasmic Domain 
The interaction of the full-length LMP1 cytoplasmic car- 
boxyl terminus (amino acids 187-386) with the LAP1 car- 
boxy-terminal 386 or 223 amino acid polypeptide scored 
higher than the positive control in the yeast two-hybrid 
dependent ~-gal assay (Table 1). The interaction of the 
membrane proximal 44 amino acids of the LMP1 cyto- 
plasmic carboxyl terminus (amino acids 187-231) with the 
LAP1 carboxy-termina1386 or 223 amino acids also gener- 
ated higher I~-gal activity than did the positive control (Ta- 
ble 1). Thus, the membrane proximal 44 amino acids of 
the LMP1 cytoplasmic carboxyl terminus and the LAP1 
carboxy-terminal 223 amino acid-TRAF homology do- 
main are sufficient for high level interaction in the yeast 
two-hybrid assay. The EBV recombinant molecular ge- 
netic evidence, which indicates that the LMP1 carbox~- 
terminal cytoplasmic domain is essential for transforma- 
tion, provides a linkage between this biochemical interaction 
and transformation. 
An EBV-Induced Cell Protein Is a 
Human TRAF1 Homolog 
LAP1 is 32% colinearly homologous to another novel hu- 
man protein that had been identified because its encoding 
mRNA is more abundant in the EBV-infected B lympho- 
blast line BL41/B95-8 than in the uninfected control BL41 
cells (Figure 1). This EBV-induced mRNA 6 (EBI6) is pre- 
dicted to encode for a 416 amino acid protein that is 86% 
colinearly identical to the murine TRAF1 (Rothe et al., 
1994) (Figure 1). EBI6 is probably the human homolog of 
murine TRAF1 since these proteins are nearly identical 
throughout heir entire sequence (Figure 1). EBI6 and 
TRAF1 have similar amino-terminal zinc finger motifs and 
are 95% identical in their TRAF domains (Figure 1). When 
fused to the GAL4-activating domain, EBI6 amino acids 
53-416 do not interact in yeast with the LMP1 carboxy- 
terminal cytoplasmic domain or with amino acids 12-568 
of LAP1 fused to the GAL4 DNA-binding domain (Table 
1). The failure of EBI6 to interact with LAP1 distinguishes 
LAP1 from the murine RING finger protein TRAF2, which 
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Figure 8. Intracellular Association of LMP1 with LAPI or EBI6 in 
Transfected BJAB, Non-EBV-lnfected, B Lymphoma Cells 
B JAB cells (10 x 106 cells per transfection) were electroporated with 
plasmids expressing the proteins indicated by a plus sign at the bottom 
of the figure. Approximately 20hr posttransfection, 4 x 106 cells from 
each transfection were lysed and subjected to immunoprecipitation 
with 10 tlg of M2 anti-FLAG monoclonal ntibody (Kodak). Equivalent 
cell lysates obtained before immunoprecipitation (la es 1-4) and im- 
munoprecipitated material ( anes 5-8) were analyzed by SDS-PAGE 
on a 7.5 % gel, transferred onto nitrocellulose, and subjected to West- 
ern blot analysis using rabbit anti-LM P1 polyclonal ntisera (Hennessy 
et al., 1984) and ~2Sl-labeled protein A, followed by autoradiography. 
The position of LMP1 is shown by the arrow, and molecular weight 
markers are shown on the right side of the panel. LMP1 was readily 
coimmunoprecipitated with FLAGLAP1 or FLAGEBI6 (lanes 6 and 7). 
No detectable LMP1 was seen in anti-FLAG immunoprecipitations 
from cells cotransfected with pSG5LMP1 and either vector control 
(pSG5) or a construct expressing a FLAG-tagged EBNA2 (FLAGE2, 
lanes 5 and 8). 
scored positive in the yeast two-hybrid system with TRAF1 
(Rothe et al., 1994). While the failure could be due to differ- 
ences between the human RING finger (LAP1) or zinc 
finger (EBI6) TRAFs and murine TRAF1 and -2, the lower 
level of homology of LAP1 to TRAF2 is more likely to ac- 
count for this discrepancy given the extensive identity be- 
tween EBI6 and LAP1. 
Expression of LAP1 and EBI6 in Human Tissues 
and Cell Lines 
The full-length 2.8 kb and alternatively spliced 1.8 kb LAP1 
mRNAs are expressed in all tissues examined (Figure 2A). 
In contrast, the 2.6 kb EBI6 mRNA is readily detected in 
lung, spleen, and tonsil, is barely detected in placenta, 
and is not detectable in pancreas, kidney, smooth muscle, 
liver, brain, or heart (Figure 2B; data not shown). To evalu- 
ate the effects of EBV infection on LAP1 and EBI6 mRNA 
abundance, LAP1 or EBI6 probes were hybridized to RNAs 
from EBV-negative BL41 B lymphoblasts, from EBV-infected 
BL41 B lymphoblasts (BL41/B95-8), or from an EBV-trans- 
formed B lymphoblast cell line (IB4) (Figures 2C and 2D). 
LAP1 mRNAs were similarly abundant in EBV-positive or 
-negative cells, whereas the EBI6 message was at least 
8-fold more abundant in the EBV-infected BL41/B95-8 or 
IB4 cells than in noninfected BL41 cells. 
LMP1 Associates with LAP1 and EBI6 
in B Lymphoblasts 
LMP1 and FLAG epitope-tagged LAP1 (FLAGLAP1) or 
FLAG-tagged EBI6 (FLAGEBI6) were expressed in an effi- 
ciently transfectable non-EBV-infected human B lympho- 
blast cell line (BJAB). As controls, LMP1 and FLAG epi- 
tope-tagged EBNA2 (FLAGEBNA2) were expressed in 
B JAB cells. Approximately 18 hr posttransfection, the cells 
were lysed in nonionic detergent; FLAG fusion proteins 
were immunoprecipitated with an anti-FLAG monoclonal 
antibody; and LMP1 was detected by Western blotting 
(Hennessy et al., 1984). LMP1 was expressed at similar 
levels in all transfections (Figure 3, lanes 1-4). A substan- 
tial fraction of LMP1 immunoprecipitated along with FLAG- 
LAP1 or FLAGEBI6 and did not immunoprecipitate along 
with FLAGEBNA2 (Figure 3, lanes 4-8). Thus, LMP1 spe- 
cifically associates with LAP1 or EBI6 in B lymphoblasts. 
LMP1 Redirects the Localization of LAP1 and EBI6 
to LMP1 Plasma Membrane Patches 
FLAG-tagged LAP1 or EBI6 expressed in BJAB cells local- 
izes throughout the cytoplasm to punctate structures that 
resemble cytoplasmic vesicles (Figures 4A and 4C). When 
LMP1 and FLAGLAP1 or FLAGEBI6 were expressed in the 
same cells, LM P1 localized to its characteristic patches or 
caps in the plasma membrane (Figures 4F, 41, 4L, 40), 
and FLAGLAP1 or FLAGEBI6 now colocalized with LMP1 
in plasma membrane patches or caps (Figures 4E and 4H 
or Figures 4K and 4N, respectively). FLAGEBI6 did not 
localize as precisely with LMP1 as did FLAGLAP1, sug- 
gesting a weaker, less direct, or more transient interaction 
with LMP1. Thus, LMP1 expression redirects LAP1 and 
(to a lesser extent) EBI6 from scattered cytoplasmic struc- 
tures to LMP1 plasma membrane patches. 
LAP1 and EBI6 Associate with TNFR Family 
Cytoplasmic-Domains 
The homology of LAP1 and EBI6 to routine TRAF2 and 
TRAF1 prompted us to examine whether LAP1 and EBI6 
can interact with members of the TNFR family, including 
CD40, lymphotoxin-I~ receptor (LTI~R), and Fas (Bancher- 
eau et al., 1994; Nagata, 1994; Smith et al., 1994; Ware 
et al., 1995), using receptor cytoplasmic domains con- 
structed as fusion proteins with glutathione S-transferase 
(GST). In vitro translated LMP1 did not interact with GST 
or GST fusions to TNFRs (Figure 5A, lanes 1-3). However, 
in vitro translated LAP1 bound specifically (112-fold over 
GST background) to the p80 cytoplasmic domain and less 
well (14-fold over GST background) to the p60 cytoplasmic 
domain (Figure 5A, lanes 4-6; Figure 5B, lanes 3 and 4; 
data not shown). LAP1 also showed nearly quantitative 
binding to the cytoplasmic domains of TNFR-related pro- 
teins CD40 and LTI~R and less efficient binding to Fas 
(Figure 5B). EBI6 bound less efficiently than did LAP1 to 
p80 and showed weak binding to p60 (Figure 5A, lanes 
7-9). 
LAP1 and EBI6 also associate with the p80 receptor in 
vivo. The p80 TNFR was coexpressed with FLAGLAP1, 
FLAGEBI6, or FLAGEBNA2 in B JAB cells that do not ex- 
press any surface pS0 receptor (data not shown). FLAG- 
tagged proteins were immunoprecipitated from cell ly- 
sates using M2 anti-FLAG antibody, and the immune 
complexes were analyzed for the presence of p80 TNFR 
by Western blotting (Figure 5C). The M2 anti-FLAG anti- 
body coimmunoprecipitated the p80 receptor from cells 
EBV LMP1 Transformation and TNFR Family Signaling 
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Figure 4. Subcellular Localization of LAP1 and EBI6 in the Presence 
or Absence of LMP1 
The intracellular distribution of FLAG-tagged LAP1 and EBI6 was de- 
termined by indirect immunofluorescence using M2 anti-FLAG mono- 
clonal antibody and rabbit anti-LMP1 polyclonal antisera. B JAB cells 
were transfected with FLAGLAP1 (A, B, and E-J) or FLAGEBI6 (C, 
D, and K-P) expressing constructs in the presence of vector pSG5 
(A-D) or pSG5LMP1 (E-P). M2 anti-FLAG reactivity was visualized 
with a fluorescein isothiocyanate-conjugated goat anti-mouse second- 
ary antibody (A, C, E, H, K, N). LMP1 was detected with a Texas Red- 
conjugated goat anti-rabbit secondary antibody (F, I, L, O). Phase- 
contrast pictures are shown in (B), (D), (G), (J), (M), and (P). M2 and 
anti-LMP1 antibodies did not show any reactivity in untransfected cells. 
No cross-reactivity was observed between M2 and the goat anti-rabbit 
secondary antibody or between the rabbit anti-LMP1 and goat anti- 
mouse secondary antibody (data not shown). 
express ing  FLAGLAP1 or FLAGESI6  (F igure 5C, lanes 1 
and 2), but not f rom cells express ing  FLAGEBNA2 (Figure 
5C, lane 3). FLAGLAP1 and FLAGEBI6  assoc ia ted  with 
both the -70  kDa precursor  and the mature  p80 TNFR 
(Ware et al., 1991), indicat ing that the assoc iat ion with 
LAP-1 occurs  pr ior  to receptor  express ion  at the cell sur-  
face.  These  s tud ies  indicate the potent ia l  of  LAP1 and 
EBI6 to part ic ipate in TNFR s ignal ing and also prov ide 
ev idence  that LAP1 may be a component  common to the 
CD40,  LTI3R, and TNFR s ignal  t ransduct ion  pathways.  
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Figure 5. Association of LAP1 and EBI6 with TNFR-Related Proteins 
(A) Cytoplasmic domains of the p60 or p80 TNFR constructed as fusion 
proteins with GST and bound to glutathione beads were incubated 
with [3~S]methionine-labeled LMP1, LAP1, or EBI6 translated in vitro 
(5 I11 reaction mix), and the fraction bound to glutathione beads was 
analyzed on a 8.5% SDS-PAGE and processed by a phosphorimager. 
Lanes 1,4, and 7 are pull downs with GST-p80; lanes 2, 5, and 8 are 
those with GST-p60; and lanes 3, 6, and 9 are those with GST-control. 
Coomassie blue staining of the gel demonstrated the presence of ap- 
proximately equivalent amounts of GST or GST-fusion proteins. 
(B) Glutathione beads containing the cytoplasmic domains of p60 (lane 
3), p80 (lane 4), Fas (lane 5), CD40 (lane 6), and LTJ3R (lane 7) ex- 
pressed as GST-fusion proteins or GST (lane 2) were incubated with 
[3SS]methionine-labeled LAP1 (2 p.I of in vitro translation reaction mix 
were used per reaction) as in (A) and were analyzed by SDS-PAGE 
and autoradiography. In vitro translated LAP1 (2 p.I) was analyzed in 
lane 1. 
(C) Coimmunoprecipitation of LAP1 and EBI6 with p80 TNFR in 
cotransfected cells. BJAB cells were cotransfected with plasmids ex- 
pressing the FLAG-tagged proteins indicated by a plus sign at the 
bottom of the figure or were left untransfected (lane 7). Approximately 
20 hr posttransfection, the cells were lysed, and lysates from 10 x 
106 cells were subjected to immunoprecipitation with M2 anti-FLAG 
monoclonal antibody. Equivalent cell lysates obtained before immuno- 
precipitation (lanes 4-7) and immunoprecipitated complexes (lanes 
1-3) were analyzed by Western blotting using an anti-p80 TNFR anti- 
body (VanArsdale and Ware, 1994). The positions of mature p80 TNFR 
and the immunoglobulin heavy chain (Ig) are shown by arrows. The 
asterisk shows the position of a precursor form of the p80 TNFR. The 
p80 receptor was readily coimmunoprecipitated with FLAGLAP1 or 
FLAGEBI6 (lanes 1 and 2). No detectable p80 receptor was immuno- 
precipitated with anti-FLAG antibody from cells cotransfected with 
plasmids expressing p80TNFR and FLAGEBNA2 (FLAGE2, lane 3). 
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Discussion 
We have identified two human TRAFs and confirmed their 
association with the human p80 TNFR. The TRAF domain 
was initially defined because of more than 50% colinear 
primary sequence identity through the carboxy-terminal 
230 amino acids of murine TRAF1 and -2 (Rothe et al., 
1994). Genetic and biochemical data link TRAF1 and -2 
to the growth and NF-•B-transducing effects of a domain 
near the carboxyt terminus of the p80 TNFR cytoplasmic 
tail (Rothe t al., 1994). EBI6 is almost certainly the human 
TRAF1, based on the ability of both proteins to associate 
with the p80 TNFR, similar tissue restricted expression, 
similar amino-terminal zinc finger motifs, 95% primary se- 
quence identity inthe TRAF domains, and an overall 86% 
colinear primary sequence identity. LAP1 is probably not 
the human TRAF2, but rather a human RING finger ana- 
log. If so, there may be one or more human RING finger 
TRAFs as yet unidentified. Although LAP1 and TRAF2 
are similar in size, have an amino-terminal RING finger 
domain, and are constitutively expressed in most tissues, 
LAP1 is 45% identical to either TRAF2 or TRAF1 in the 
TRAF domain and is quite divergent from TRAF2 outside 
of the TRAF domain. Overall, LAP1 and TRAF2 are only 
27% identical. LAP1 also appears to be functionally dis- 
tinct from TRAF2 in not directly interacting with EBI6, the 
human TRAFI. 
LAP1 and EBI6 interact with the cytoplasmic domain of 
not only p80 TNFR but also with p60 TNFR, albeit less 
well than with p80. This is the first evidence of interaction 
beyond p80 between these putative effectors and the 
TNFR family. Indeed, LAP1 also interacts trongly with 
the LTI3R and CD40 cytoplasmic domains. These findings 
provide a new molecular basis for understanding the com- 
mon effects of activation of these members of the TNFR 
family. Heterogeneity among TRAFs or other cell proteins 
may provide components to the receptor-TRAF com- 
plexes that determine the specific phenotypic outcome(s) 
of receptor activation. 
The identification of these human TRAFs is in the con- 
text of an investigation into the mechanisms by which 
LMP1 transforms cells. These biochemical and genetic 
experiments and previous EBV recombinantmolecular 
genetic analysis establish a connection between the role 
of LMP1 in B lymphocyte growth transformation and TNFR 
signaling pathways. As briefly reviewed in the introduction, 
LMP1 is a dominant oncogene that has multiple down- 
stream effects on cell growth and gene expression, at least 
some of which are NF-KB mediated. LMP1 interacts 
strongly and directly with LAP1 and also associates with 
EBI6 in human lymphoblasts. Our genetic, biochemical, 
and intracellular localization data on the association of 
~LMP1 with LAP1 and EBI6, taken together with the previ- 
ous genetic and biochemical linkage of TRAF1 and -2 to 
p80 TNFR signaling, reinforce a role for the TRAFs as 
mediators of cell growth or death and NF-~B responses 
(for schematic model, see Figure 6). , 
The six markedly hydrophobic transmembrane domains 
of LMP1 enable it to aggregate in the plasma membrane 
and to present aggregated cytoplasmic domains to the 
A T T 
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Figure 6. Schematic Representation of p80 TNFR Activation and 
LMP1 Complexes at the Plasma Membrane 
(A) Model forthe activation of the p80 TNFR is shown. The extracellular 
region of the TNFR is composed of four domains with characteristic 
cysteine patterns. The cytoplasmic domain of the receptor is known 
to associate with complexes of TRAF molecules (TRAF), including 
TRAF1, TRAF2, and LAP1. Upon binding of TNF (shown here as a 
trimer), the extracellular domains of several receptor molecules are 
believed to be cross-linked, causing aggregation of intracellular do- 
mains and their associated TRAF molecules. Clustering of receptor 
molecules and their intracellular domains results insignal transduction 
as manifested by a number of phenotypic alterations, including the 
activation of transcription factor NF-KB (NFkB) and cell growth. 
(B) Three LMP1 molecules are shown to form a constitutive complex 
at the plasma membrane (depicted by the stippled area between the 
two solid horizontal lines). The amino-terminal (N) and carboxy- 
terminal (C) cytoplasmic regions of LMP1 are shown by short and long 
lines, respectively. The transmembrane domains of LMP1 are depicted 
by vertical cylinders, which are joined by short reverse turns (short 
curved lines). Aggregation of LMP1 molecules at the plasma mem- 
brane brings together LMPl-associated TRAF molecules ('rRAF) in a 
complex, thus, generating a constitutive signal that results in pleiotro- 
pic effects, including activation of NF-KB (NFkB) and cell growth. 
TRAFs (Figure 6B). In presenting aggregated TRAF- 
interacting domains, LMP1 mimics TNFR aggregation, 
which appears to be essential for signal transduction (En- 
gelmann et al., 1990; Loetscher et al., 1991; Pennica et 
al., 1992; Tartaglia and Goeddel, 1992). Receptor cross- 
linking probably locally aggregates TRAFs and associated 
molecules, creating a second messenger signal perhaps 
mediated by a receptor-associated serine/threonine ki- 
nase (Figure 6A) (Darnay et al., 1994a, 1994b; VanArsdale 
and Ware, 1994). Since LMP1 constitutively aggregates 
EBV LMP1 Transformation and TNFR Family Signaling 
395 
LAP1 and EBI6 in oligomeric complexes at plasma mem- 
brane patches, these complexes could constitutively 
activate growth signals and NF-KB in the absence of 
extracellular stimuli (Figure 6B). LM P1 signaling via TRAF 
molecules may thus proceed independently of TNFR mol- 
ecules. Alternatively, LMP1-TRAF aggregates may nucle- 
ate larger, more diverse, or more stable TNFR family- 
TRAF complexes through interactions among the extended 
coiled-coils of the TRAF domains. In fact, some evidence 
favors the latter alternative in that lymphotoxin-~ (LT(~) is 
an autocrine growth factor for EBV-transformed lympho- 
blastoid cell lines (Estrov et al., 1993; Gibbons et al., 1994). 
Furthermore, expression of the full range of EBV latent 
infection-associated proteins in Burkitt lymphoma cell 
lines induces LTa and the p80 receptor (Gibbons et al., 
1994). Moreover, antagonistic antibodies to the p60 TNFR 
have a negative growth effect in such cells (Gibbons et 
al., 1994). The LMP1 cytoplasmic carboxy-terminal do- 
main and TNFR family members could even interact with 
different domains of the same LAP1 molecule since there 
is no obvious homology between the LMP1 cytoplasmic 
carboxyl terminus and the cytoplasmic domains of TNFR 
family members. 
The induction of EBI6 by latent EBV infection and the 
association of EBI6 with I_MP1 in B lymphoblasts are also 
evidence of an important role for EBI6 in EBV-mediated 
B lymphocyte growth transformation. The interaction ap- 
pears to be less direct than with LAP1 and may be medi- 
ated by another as yet unidentified human RING finger 
TRAF. 
TNF and CD40 ligand are well known mediators of 
growth of B lymphocytes and of other cell types that are 
targets for LMPl-transforming effects (Noelle et al., 1992; 
Boussiotis et al., 1994). In fact, CD40 ligation and interleu- 
kin-4 treatment are sufficient to sustain the proliferation 
of primary B lymphocytes in vitro for several months, and 
the cells are phenotypically similar to EBV-transformed 
lymphocytes (Saeland et al., 1993; Banchereau et al., 
1994; Galibert et al., 1994). The LTI3R is expressed on 
epithelial cells (C. W. and J. Browning, unpublished ata), 
while basal epithelial cells and anaplastic nasopharyngeal 
carcinoma cells also express high levels of CD40 (Busson 
et al., 1988; Young et al., 1989). LMP1, through constitu- 
tive direct interaction with LAP1, may amplify or usurp 
LTI~R and CD40 signal transduction and constitutively pro- 
mote cell growth. Nasopharyngeal carcinoma is tightly as- 
sociated with EBV, and LMP1 is frequently expressed in 
the tumor cells (Brooks et al., 1992). Hodgkin's disease 
is another EBV-associated malignancy in which LMP1 is 
expressed (Herbst et al., 1991). CD40, TNFRs, and the 
related receptor CD30 are up-regulated in Hodgkin's dis- 
ease cells (Froese et al., 1987; Pfreundschuh et al., 1989; 
Carde et al., 1990; O'Grady et al., 1994; Trumper et al., 
1994). A potentially important consequence of the demon- 
strated interaction between LAP1 and LMP1 is that inhibi- 
tors of that interaction may affect the growth or development 
of these LMPl-associated malignancies. 
In interacting with components of receptor signaling, 
LMP1 is reminiscent of bovine papilloma virus E5. Bovine 
papilloma virus E5 dimerizes in the plasma membrane, pre- 
sumably through hydrophobic interactions, and activates re- 
ceptors for epidermal growth factor, platelet-derived growth 
factor, or colony-stimulating factor 1 (Martin et al., 1989; 
Petti et al., 1991; Petti and DiMaio, 1992). E5 binds a 
component of vacuolar H+-ATPases, and this may affect 
receptor recycling (Goldstein et al., 1991). 
A curious aspect of our data is the finding that LAP1 or 
EBI6 localized to vesicle-like structures in the cytoplasm 
of B lymphoblasts. Furthermore, LAP1 is constitutively ex- 
pressed in cells, and there may be another constitutively 
expressed RING finger protein that intermediates between 
LMP1 and EBI6. These Constitutively expressed proteins 
may also have a role in vesicle biology. 
The interaction of LMP1 with TNFR signaling pathways 
may also be important in enabling EBV-infected cells to 
evade cellular host defense mechanisms in latent or lytic 
EBV infection. LMP1 is one of the few EBV genes ex- 
pressed in both phases of the virus life cycle (Mann et al., 
1985; Rowe et al., 1992). Several virus families appear to 
specifically target the TNF/lymphotoxin pathways, pre- 
sumably to avoid these immune cell mediators of cytotox- 
icity. Pox viruses produce soluble versions of the p80 
TNFR (Smith et al., 1991; Massung et al., 1993); proteins 
encoded by the adenovirus E3 region block the apoptotic 
function of TNF (Gooding, 1992); and HIV utilizes NF-KB- 
activating signals induced by TNF signaling to enhance 
transcription (Poli et al., 1990). The binding of EBV LMP1 
to LAP1 may effectively compete with normal LAP1 bind- 
ing to the p60 TNFR, blocking the induction of cell death 
mediated by that receptor (Tartaglia et al., 1993b) or 
blocking other functions critical to host defense (Pfeffer 
et al., 1993; Rothe et al., 1993), while simultaneously usurp- 
ing the growth-promoting signals of the ~)80 TNFR (Tartag- 
lia et al., 1993a). 
Experimental Procedures 
Plasmid Construction 
The GAL4 DNA-binding domain (G4DBD) fusions were constructed 
in vector pAS2 (Harper et al., 1993). G4DBDLMPI(187-386) was con- 
structed by polymerase chain reaction-mediated (PCR-mediated) am- 
plification of the LMP1 cDNA fragment, encoding amino acids 187- 
386, using oligos L1-5PCR (5'-CGCGGATCCATGGACAACGACA- 
CAGTG-3') and L1-4PCR (5'-CGCGGATCCTTAGTCATAGTAGCT- 
TAG-39, followed by cloning into the BamHI site of pAS2. G4D- 
BDLMP1(187-231) was constructed by PCR amplification ofthe LMP1 
cDNA fragment, encoding amino acids 187-231, using oligos L1- 
5PCR and LCA231 (5"CGCGGATCCTTAGGCTCCACTCACGAG- 
CAG-3~, followed by cloning into the BamHI site of pAS2. G4DBDL- 
AP1(12-568) was constructed by isolating the BssHII-BamHI 
fragment of LAP1 cDNA from pSG5LAP1, blunt-ending it using T4 
DNA polymerase, and subcloning it into the Smal site of pASI. GAL4 
transactivating domain (G4TAD) fusions were as follows. G4TA- 
DEBI6(53-416) was constructed by subcloning the Bglll fragment of 
EBI6 cDNA into the BamHI site of pACTII (a gift of S. EUedge). G4TA- 
DEBI6(53-416) encodes for an in-frame fusion of EBI6 amino acids 
53-416 to the acidic transactivating domain of GAL4. Plasmids 
G4TADLAP1 (183-568) and G4TAD LAP1(345-568) were isolated from 
the yeast wo-hybrid screening. Plasmids expressing SNF1 fused to 
the DNA-binding domain of GAL4 (G4DBDSNF1) or SNF4 fused to 
the activation domain of GAL4 (G4TADSNF4) were gifts of S. Elledge. 
SNF1 and SNF4 are two yeast proteins that are known to interact with 
each other, and they were used as a positive control in the yeast 
two-hybrid-dependent l}-gal assay (Harper et al., 1993). LAP1 cDNAs 
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were subcloned into the EcoRI site of plasmid pSG5 (Stratagene) for 
sequencing analysis, pSG5 subclones of the longest LAP1 cDNAs 
were spliced at the Nrul site to generate the full-length LAP1- 
expressing construct pSG5LAP1. The EcoRI insert of Zgtl0 clone EBI6 
was subcloned into the plasmid pBluescript for sequencing analysis. 
pSG5FLAGLAP1 and pSG5FLAGEBI6 were constructed in vector 
pSG5 by placing through PCR a FLAG-encoding DNA fragment just 
after the initiator AUG codon. Expression plasmids for TNFRs were 
previously described (Ware et al., 1991). 
Subtractive Hybridization 
Construction of the ~.gtl 0 cDNA library from the EBV-positive cell line 
BL41/B95-8 was previously described (Birkenbach et al., 1993). Sub- 
tractive hybridization and homology screening of the Xgtl0 library was 
done as described before (Birkenbach et al., 1993). 
Yeast Two-Hybrid Screening 
Yeast transformation was performed according to the method of 
Schiestl and Geitz (1989). The yeast strain Y190 (Du rfee et al., 1993) 
was transformed with plasmid construct G4DBDLMP 1(187-386), and 
transformants were plated on Trp selective-defined media. A single 
colony was picked, and the expression of the LMP1 fusion protein 
was verified by Western blotting using the $12 anti-LMP1 monoclonal 
antibody. The G4DBDLM P 1 (187-386) transformant was subsequently 
transformed with a cDNA library constructed previously from an EBV- 
transformed lymphoblastoid cell line (Durfee et al., 1993), and selec- 
tion was done on Trp Leu- His- selective-defined media in the pres- 
ence of 25 mM 3-aminotriazole (Sigma) as previously described 
(Durfee et al., 1993). Colonies that showed moderate to intense growth 
were streaked on Trp- Leu- Hi~ selective-defined media containing 
50 mM 3-aminotriazole and tested for 13-gal expression by a filter lift 
assay (Breeden and Nasmyth, 1985). For quantitation of ~-gal expres- 
sion, yeast clones were grown in appropriate selective media to ODsoo 
of 0.5-1.2 and were assayed for ~-gal activity using ONPG and stan- 
dard conditions as previously described (Breeden and Nasmyth, 
1985). I~-Gal units were expressed as (1000/hls)/(assay time in mi- 
nutes)(ceU culture volume in milliliters)(OD~). The interactions of 
G4DBD with G4TADLAPl(183-568), G4TADLAPl(346-568), or 
G4TADEBI6(53-416) and of G4TAD with G4DBDLMP1(187-386), 
G4DBDLMPl(187-231), or G4DBDLAP1(12-568) scored ~<0.1 U of 
~-gal. Library-derived piasmids were recovered by transformation of 
competent bacteria with total yeast DNA preps, followed by selection 
for ampicillin resistance as previously described (Ausubel et al., 1987). 
Northern Blots 
Northern blots containing poly(A) ÷ RNA (2 p.g per lane) from eight 
human tissues were purchased from CLONTECH. RNA was prepared 
from EBV-positive (BL41/B95-8) or EBV-negative (BL41) Burkitt's 
lymphoma cell lines and a lymphoblastoid cell line (IB4) as previously 
described (Birkenbach et al., 1993). cDNA probes were labeled by 
random hexanucleotide priming (Stratagene) using [32P]dCTP. The 
RNA blots were hybridized to 32P-labeled cDNA probes under high 
stringency conditions as described (Mosialos et al., 1994). Northern 
blot filters were exposed to autoradiography film or were processed 
by phosphorimager analysis. 
Immunoprecipitations, Western Blotting, 
and Immunofluorescence 
BJAB cells were eiectroporated at 220 V and 960 p~F in 400 pl of 
RPMI-1640 medium containing 10% fetal calf serum. Approximately 
20 hr posttranfection, cells were lysed for 30 rain on ice in 0.5% NP-40 
lysis buffer containing 50 mM HEPES (pH 7.4), 250 mM NaCI, 10% 
glycerol, 2 mM EDTA, 1 mM PMSF, 2 i~g/ml aprotinin, 2 i~g/ml pepstatin 
A, and 2 ~g/ml leupeptin. Cell debris were removed by centrifugation 
at 10,000 x g for 10 rain at 4°C. The cell lysates were precieared 
with protein G-Sepharose beads for I hr at 4°C. The primary antibody 
was then added for 1 hr at 4°C, and immunoglobulin complexes were 
collected on protein G-Sepharose beads for 1 hr at 4°C. The beads 
were then washed six times with 1 ml of lysis buffer each time, and 
protein complexes were recovered by boiling in SDS sample buffer 
and were analyzed by SDS-polyacrylamide gel electrophoresis (SDS- 
PAGE). Western blotting was done using standard techniques as pre- 
viously described (Mosiales et al., 1994). 
Indirect immunofluorescence analysis on transfected cells was 
done approximately 18-20 hr posttransfection as previously described 
(Mosialos et al., 1994). 
Production and Purification of GeT-Fusion Proteins 
The cytoplasmic domains Of the p80 and p60 TNFRs were amplified 
from the corresponding cDNAs by PCR and were cloned in frame into 
the pGEX-4T-1 expression vector (Pharmacia) using the EcoRI and 
Xhol restriction sites for the p60 TNFR and the EcoRI and Xhol sites 
for the p80 TNFR. A similar strategy was employed for the construction 
of a GST fusion to the LT~R cytoplasmic domain. GST-fusion proteins 
of the cytoplasmic domains of CD40 and Fas were a gift of J. Reed 
(La Jolla Cancer Research Institute). Expression and purification of 
GST-fusion proteins were performed essentially as described pre- 
viously (Smith and Johnson, 1988). Fusion protein concentrations of 
3-5 mg/ml of glutathione-agarose beads (Pharmacia) were routinely 
obtained. In vitro translations were done using the rabbit reticulocyte- 
coupled in vitro transcription translation system (TNT, Promega) ac- 
cording to the protocol of the manufacturer. In vitro translated proteins 
were diluted with binding buffer (PBS containing 0.1% NP-40, 0.5 
mM DTT, 10% glycerol, 1 mM PMSF, 2 i~g/mi aprotinin) and were 
preclearad with glutathione beads for 45 rain at 4°C. GST or GST- 
fusion proteins bound to glutathiene beads were then incubated with in 
vitro translated proteins for 1 hr at 4°C. The beads were subsequently 
washed five times with 0.5 ml of binding buffer each time, and bound 
proteins were recovered by boiling in SDS sample buffer and were 
analyzed by SDS-PAGE. 
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Note Added in Proof 
In the December 2, 1994 issue of the Journal of Biological Chemistry, 
Hu et al. reported the sequence of a protein that is nearly identical to 
that of LAP1. This protein became bound to wild type, but not to a 
signaling-defective mutant CD40 cytoplasmic domain. 
